Poseida Therapeutics Inc., a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, has nominated a new development candidate under its collaboration with Roche.   The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma.   The large capacity of Poseida’s non-viral transposon-based D...